Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026
Basics
Sector
Healthcare
Industry
Health Information Services
Country
United States
Market cap
49.1B USD
Enterprise value
42.0B USD
Full-time employees
7,928
Overall health
Strength:lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity
Drawback:its share price swings more than most peers’ (beta 0.97 vs a peer median of 0.63), though less than the overall marketbigger price swings (beta 0.97 vs peers 0.63)
About average: valuation
Ranks #156 of 1,157 healthcare companies (top 14%)
Stock pay outran buybacks. Stock-based pay expense $1.3B vs $170M spent repurchasing shares over the 3 fiscal years to FY Jan 2026.
Over three fiscal years Veeva Systems recorded $1.3B of stock-based pay expense and spent $170M repurchasing shares (repurchases can include shares withheld to cover employees' taxes). Repurchases were smaller than the stock pay, so they did little to offset new employee shares.Over three fiscal years Veeva Systems recorded $1.3B of stock-based pay expense and spent $170M repurchasing shares. Repurchases were smaller than the stock pay, so they did little to offset new employee shares.
Stock-based pay is a large cost. Stock pay was 15% of revenue in FY Jan 2026.
Veeva Systems paid employees $473M in stock in FY Jan 2026, 15% of its $3.2B revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Operating margin at a 6-year high.29% in FY Jan 2026, the best of the last 6 years.
Veeva Systems kept 29% of revenue as operating profit in FY Jan 2026, its highest in the 6 years of filings we have.
Profits growing faster than sales. Since FY Jan 2023: revenue +48%, operating profit +100%.
Since FY Jan 2023, Veeva Systems's revenue grew 48% while operating profit grew 100%: each extra dollar of sales is adding more profit.
StockQuotient Score
69/ 100▼ 1 since Oct 27 closeOct 5 70 → Nov 4 69 (-1)
Why it changed since the Oct 27, 2026 close: Score 70 → 69
Peer companies moved-1
Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.
Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 0.99Sector median: 0.2215 · MAD: 0.2039
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Veeva Systems
Is Veeva Systems getting weaker?
Its latest SEC filing (Aug 27, 2026) showed no major changes. Its overall score is 69/100, down 1 since Oct 28, 2026.
How is Veeva Systems valued vs its peers?
Priced about in line with its peers. Valuation scores 46/100 against 1,393 healthcare peers.
Is Veeva Systems growing?
Yes, faster than most of its peers. Growth scores 69/100 against 1,393 healthcare peers.3-year revenue growth 15.7% vs a peer median of 5.8% (stronger than 75% of peers).3-year revenue growth 15.7% vs peers 5.8% (stronger than 75% of peers).
How profitable is Veeva Systems?
More profitable than most of its peers. Profitability scores 90/100 against 1,393 healthcare peers.Operating margin 29.9% vs a peer median of 7.1% (stronger than 93% of peers).Operating margin 29.9% vs peers 7.1% (stronger than 93% of peers).
How risky is Veeva Systems?
Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Debt / equity 0.02× vs a peer median of 0.22× (stronger than 84% of peers).Debt / equity 0.02× vs peers 0.22× (stronger than 84% of peers).Beta 0.97 vs a peer median of 0.63 (weaker than 70% of peers).Beta 0.97 vs peers 0.63 (weaker than 70% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Jul 31, 2026 · filed Aug 27, 2026 · compared with the quarter ended Apr 30, 2026
No major changes
Previous quarter
Latest quarter
Change
Revenue (12 months)
3.3B USD
3.5B USD
+4.2%
Net income (12 months)
941.7M USD
1.0B USD
+7.8%
Operating margin
28.8%
29.9%
+1.1 pts
Cash
1.9B USD
1.8B USD
−4.5%
Shares outstanding
162.4M
161.9M
−0.3%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Health Information Services companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY Jan 2022
FY Jan 2023
FY Jan 2024
FY Jan 2025
FY Jan 2026
Change
Gross margin
72.8%
71.7%
71.3%
74.5%
75.5%
▲ 1.0 pts
Operating margin
27.3%
21.3%
18.2%
25.2%
28.7%
▲ 3.5 pts
Net margin
23.1%
22.6%
22.2%
26.0%
28.4%
▲ 2.4 pts
Return on assets (ROA)
11.2%
10.2%
8.9%
9.7%
10.1%
▲ 0.4 pts
Return on equity (ROE)
14.7%
13.1%
11.3%
12.2%
12.6%
▲ 0.4 pts
Current ratio
3.70×
3.94×
4.24×
4.51×
4.89×
▲ 8.3%
VEEV price history
Price history is added with the daily price update and will appear after the next one.